The tweet was deleted by the author.
But we saved everything 🙂.
Biohaven will present new data from its investigational BHV-1530 program at ESMO2026. The company shared the update on social media.
Biohaven stated that it remains committed to advancing innovative approaches in oncology. The team will share the latest research with the global cancer community.
Biohaven (BHVN) is trading at $15.41, sitting just above the MA-20 ($15.40), and significantly higher than MA-50 ($12.44) and MA-200 ($11.65), which confirms a bullish structure across all timeframes. The Ichimoku Kijun on D1 is at $14.12, which is below the current price and therefore acts as immediate support. Near-term support is clustered near the Kijun at $14.12, while key support lies at MA-50 ($12.44). Near-term resistance is at MA-20 ($15.40), with key resistance at MA-10 ($15.40) and further out at the 52-week high of $18.57.
Momentum remains positive with a strong buy signal from MACD on D1 and a firm bullish bias from ADX (32.04), though most short-term moving averages signal overextension. RSI on D1 sits at 53.31, suggesting neutral-to-slightly bullish conditions, while Stoch RSI is oversold, and CCI is neutral, indicating mixed short-term momentum. BBP is overbought at 0.59, showing buyers dominate intraday dynamics. The Awesome Oscillator remains neutral and does not provide significant confirmation. In today’s session, BHVN gained 3.70%. Over the past week, the stock is virtually flat, trading at $15.41 compared to a previous weekly close of $15.44, reflecting a slight 0.45% pullback. Price is at the very top of the weekly range (near resistance), with volatility amplitude reaching 13.95%. This follows a recovery from the weekly low and signals a potential pause or consolidation after testing resistance.
Looking ahead, the expected trading range for the coming week is $14.65 to $16.90, keeping BHVN securely above its 52-week low of $7.48 and well below its 52-week high of $18.57. With three out of four W1 indicators (RSI, MACD, MA-50) giving Buy signals and only ADX W1 staying neutral, the probability of a price increase is high (more than 80%), while the chance of a decline is very low. The baseline scenario anticipates consolidation within this new higher band. A bullish breakout above $16.90 could open a quick move toward the former yearly highs. Conversely, a drop below support at $14.12 would expose BHVN to a deeper pullback toward $12.44.
Previously it was reported that Biohaven exhibited a bullish medium-term structure but faced near-term consolidation as momentum indicators signaled mixed trading conditions. Developments since then will require close monitoring of momentum shifts, with particular focus on whether the stock can sustain upward movement to confirm a breakout scenario.